Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

F573 for Injection for the Treatment of Liver Injury/Failure : Randomized, Double-blind, Placebo-controlled Phase Ⅱa Clinical Trial

NCT05689645 is registered in ClinicalTrials.gov with Beijing Continent Pharmaceutical Co, Ltd. as lead sponsor.

NCT NCT05689645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05689645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
F573 for Injection for the Treatment of Liver Injury/Failure : Randomized, Double-blind, Placebo-controlled Phase Ⅱa Clinical Trial
Lead sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 24, 2023
Completion date
September 1, 2026
Enrollment
97 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute liver failure, acute-on-chronic liver failure